Top Markets
Coin of the day
Marizyme, Inc. Marizyme, Inc.

Marizyme, Inc.

MRZM
株式のランク #41141
Marizyme, Inc. is a life sciences company primarily engaged in bringing... Marizyme, Inc. is a life sciences company primarily engaged in bringing innovative medical technologies from development to market. Its offerings include DuraGraft, a unique single-application treatment administered during vascular and bypass surgeries, engineered to maintain the function and structure of the endothelium, along with other critical characteristics. The company is also progressing with various therapeutic products utilizing its Krillase protease-based platform. These are being developed to address conditions such as severe wounds and burns, acute ischemic stroke, deep vein thrombosis, and for the removal of dental plaque and biofilms. Additionally, Marizyme focuses on creating solutions to mitigate the damaging effects of ischemia-reperfusion injury in different grafting and organ transplantation procedures, among other medical applications. A further key initiative is the development of MATLOC, a digital, point-of-care, lab-on-chip device platform designed for the screening and diagnosis of chronic kidney disease. Established in 2007, Marizyme, Inc., previously known as GBS Enterprises Incorporated, is headquartered in Jupiter, Florida.
株価
$0.0003
最終同期: 2026-08-11
時価総額
$39.54K
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Marizyme, Inc. (MRZM)

カテゴリー

Marizyme, Inc.(MRZM)のP/S比率
2026 時点のP/S比率 TTM: 0
Marizyme, Inc. の最新の財務報告および株価によると、現在のP/S比率(TTM)は 0 です。2026 年末時点でのP/S比率は 0 でした。
Marizyme, Inc. の P/S 比率の履歴(2026 ~ 2026)
各年末時点のP/S比率
P/S比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/S比率